Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annexon, Inc. - common stock (NQ:ANNX)

1.745 +0.065 (+3.87%)
Streaming Delayed Price Updated: 2:34 PM EDT, Apr 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,018,186
Open 1.720
Bid (Size) 1.740 (34)
Ask (Size) 1.750 (15)
Prev. Close 1.680
Today's Range 1.620 - 1.790
52wk Range 1.285 - 7.850
Shares Outstanding 47,722,995
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder
Annexon's tanruprubart showed significant and sustained functional gains in Guillain-Barré patients, meeting key Phase 3 trial endpoints. 
Via Benzinga

Performance

YTD
-68.3%
-68.3%
1 Month
-35.4%
-35.4%
3 Month
-58.2%
-58.2%
6 Month
-76.7%
-76.7%
1 Year
-61.6%
-61.6%

More News

Read More
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
From Annexon Biosciences
Via GlobeNewswire
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
From Annexon Biosciences
Via GlobeNewswire
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
From Annexon Biosciences
Via GlobeNewswire
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
From Annexon Biosciences
Via GlobeNewswire

Frequently Asked Questions

Is Annexon, Inc. - common stock publicly traded?
Yes, Annexon, Inc. - common stock is publicly traded.
What exchange does Annexon, Inc. - common stock trade on?
Annexon, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Annexon, Inc. - common stock?
The ticker symbol for Annexon, Inc. - common stock is ANNX on the Nasdaq Stock Market
What is the current price of Annexon, Inc. - common stock?
The current price of Annexon, Inc. - common stock is 1.745
When was Annexon, Inc. - common stock last traded?
The last trade of Annexon, Inc. - common stock was at 04/22/25 02:34 PM ET
What is the market capitalization of Annexon, Inc. - common stock?
The market capitalization of Annexon, Inc. - common stock is 83.28M
How many shares of Annexon, Inc. - common stock are outstanding?
Annexon, Inc. - common stock has 83M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.